This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A Busy Calendar of March Biotech Events

By: Adam Feuerstein | 03/03/14 - 01:13 PM EST

March is a catalyst-rich month for biotech and drug stocks. 

Two FDA drug approval decisions this month. On March 19, Endo Health's (ENDP) Impavido to treat leishmaniasis, and on March 21, Celgene's (CELG) Otezla for psoriatic arthritis.

In Europe, Endocyte (ECYT) and Merck (MRK) are expecting a decision on accelerated approval for their ovarian cancer therapy vintafolide following the CHMP meeting scheduled for March 17-20. The announcement decision will come no later than March 21.

Three significant FDA advisory committee meetings to look forward to later this month.

On March 26-27 the FDA's Molecular and Clinical Genetics Panel will review two non-invasive screening tests for colon cancer: Epigenomics' blood-based Epi proColon and Exact Sciences' (EXAS) stool-based Cologuard. Look for FDA briefing documents for Epigenomics on March 24 and Exact Sciences on March 25.

On March 31, the FDA's Anti-Infective Drugs Advisory Committee will review two new antibiotics: Cubist Pharmaceuticals' CBST tedizolid and Durata Therapeutics' (DRTX) dalbavancin. FDA briefing documents will be posted to the agency's web site on March 27.

On April 1, the Endocrinologic and Metabolic Drugs Advisory Committee will review MannKind's (MNKD) inhaled, rapid-acting insulin Afrezza. The Afrezza FDA panel counts as a March event because FDA briefing documents will be made available on March 28.

On the clinical side:

Top-line results from a phase II study of Insmed's (INSM) Arikace in lung disease caused by nontuberculous mycobacteria (NTM).

Top-line results from a phase II study of Endocyte and Merck's vintafolide in non-small lung cancer.

Prana Biotech (PRAN) will announce results from a phase II study of PBT2 in Alzheimer's disease.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs